Physician profile
Michael B Adenaike
NPI 1700049939
$14,197.57
in general payments reported to CMS, 2019-2025
21 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $251 · 2021: $386 · 2022: $688 · 2023: $632 · 2024: $12K · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $1,930 · Travel and Lodging: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,364.00 |
| Food and Beverage | $1,930.40 |
| Travel and Lodging | $199.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11,016.96 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $782.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $481.18 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.40 | 2020-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $227.48 | 2020-2025 | Eliquis, Camzyos |
| Pfizer INC. | $219.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $204.02 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $155.71 | 2020-2023 | |
| Amgen INC. | $153.89 | 2021-2024 | Repatha |
| Novo Nordisk INC | $139.27 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $139.15 | 2024 | Arcalyst |
| Heartflow, INC. | $129.33 | 2025 | |
| Sanofi-Aventis U.S. LLC | $106.79 | 2022-2024 | |
| Lantheus Medical Imaging, INC. | $36.48 | 2023-2024 | Definity |
| Esperion Therapeutics, INC. | $34.68 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.15 | 2023-2024 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $28.23 | 2021 | |
| Scpharmaceuticals INC. | $21.75 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.87 | 2023 | |
| Lundbeck LLC | $16.93 | 2019 | |
| Altathera Pharmaceuticals LLC | $16.17 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Adenaike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.